Compare Novavax Inc (NVAX) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs State Street SPDR S&P Homebuilders ETF — how do they compare? Novavax Inc trades at $12.7 (market cap $1.82B), while State Street SPDR S&P Homebuilders ETF trades at $94.83 (market cap $1.49B). The key difference: Novavax Inc is the larger of the two by market cap, and Novavax Inc is trading nearer its 52-week high, State Street SPDR S&P Homebuilders ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and State Street SPDR S&P Homebuilders ETF for 33 Days on average.
| NVAX | XHB | |
|---|---|---|
Market Cap | $1.82B | $1.49B |
Volume | 6,198,505 | 2,445,587 |
Sector | Health | Broad Market / Factor |
52-Week High | $12.56 | $121.36 |
52-Week Low | $6.22 | $94.86 |
Typical Hold Time | 59 Days | 33 Days |
Enterprise Value | $1.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
XHB (SPDR S&P Homebuilders ETF) trades at $94.77, down 0.13% with a bearish technical outlook from moving averages. The ETF tracks homebuilder stocks facing headwinds from rising mortgage rates near 7%, though recent news highlights potential buying opportunities amid sector undervaluation. Technical indicators show neutral oscillators but bearish momentum with support at $94 and resistance at $96.
The housing market faces mixed signals with rising rates pressuring affordability, but legislative support and institutional interest suggest long-term potential. Key risks include mortgage rate volatility and economic sensitivity, while analyst coverage emphasizes sector recovery prospects. Investment appeal hinges on housing market stabilization and policy impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
